LFMD LIFEMD INC

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026.

About LifeMD, Inc.



LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, spanning primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit .

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact                                

Marc Benathen, Chief Financial Officer

Media Contact

Jessica Friedeman, Chief Marketing and Product Officer



EN
26/12/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LIFEMD INC

 PRESS RELEASE

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Pr...

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026. About LifeMD, Inc.LifeMD® is a leading provide...

 PRESS RELEASE

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIM...

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026 NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the 2025 Deloitte Technology Fast 500™ and the inaugural TIME’s America’s Growth Leaders of 2026 lists. These distinguished awards reflect LifeMD’s continued revenue growth, financial stability, and emerging leadership position in the health technology sector. “Inclusion on these lists of North America...

 PRESS RELEASE

LifeMD Reports Third Quarter 2025 Results

LifeMD Reports Third Quarter 2025 Results Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million.Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million.Paid off all outstanding debt during the quarter.Subsequent to quarter end, fully divested our majority stake in WorkSimpli, positioning LifeMD as a pure-play telehealth and pharmacy platform.Continued to diversify clinical platform with new launches in women’s health, men’s health and psychiatry. Conference call begins at 4:30 p.m. East...

 PRESS RELEASE

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® ...

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality care NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy® and Ozempic®, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will now offer the 0.25 m...

 PRESS RELEASE

LifeMD to Participate in the BTIG Digital Health Forum

LifeMD to Participate in the BTIG Digital Health Forum NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced its participation in the virtual BTIG Digital Health Forum on November 24, 2025. Management will participate in a virtual panel discussion titled “Creating a Scalable Virtual Primary Care and Obesity Health Platform” at 4:00 p.m. Eastern time and will be available for one-on-one virtual meetings. Investors can register for the conference by contacting their BTIG representative. About LifeMD, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch